Vantage logo

Novartis trims its pipeline

Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.

Vantage logo

Biotech’s near-term key catalysts

Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.

Vantage logo

Unpacking Royalty Pharma

The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.